REGEN-COV, 5-cartons (casirivimab 300 mg in 2.5 mL Injection, 4 vial / imdevimab 1332 mg in 11.1 mg Injection, 1 vial) (EUA)
RxNorm 2479156

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2479156 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: REGEN-COV, 5-cartons (casirivimab 300 mg in 2.5 mL Injection, 4 vial / imdevimab 1332 mg in 11.1 mg Injection, 1 vial) (EUA).

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
REGEN-COV, 5-cartons (casirivimab 300 mg in 2.5 mL Injection, 4 vial / imdevimab 1332 mg in 11.1 mg Injection, 1 vial) (EUA)
AUI:12539667
View
SY
REGEN-COV, 5-cartons (casirivimab 4, imdevimab 1) (EUA)
AUI:12539666
View
BPCK
{1 (11.1 mL imdevimab 120 mg/ML Injection) / 4 (2.5 mL casirivimab 120 mg/ML Injection) } Pack [REGEN-COV 4/1]
AUI:12539665
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSN

Prescribable Name (PSN):
REGEN-COV, 5-cartons (casirivimab 300 mg in 2.5 mL Injection, 4 vial / imdevimab 1332 mg in 11.1 mg Injection, 1 vial) (EUA)
(Atom ID: 12539667)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
REGEN-COV, 5-cartons (casirivimab 300 MG in 2.5 mL Injection, 4 vial / imdevimab 1332 MG in 11.1 MG Injection, 1 vial) (EUA)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2479156
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539667
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2479156
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SY

Synonym (SY):
REGEN-COV, 5-cartons (casirivimab 4, imdevimab 1) (EUA)
(Atom ID: 12539666)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
REGEN-COV, 5-cartons (casirivimab 4, imdevimab 1) (EUA)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2479156
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539666
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2479156
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
BPCK

Brand Name Pack (BPCK):
{1 (11.1 mL imdevimab 120 mg/ML Injection) / 4 (2.5 mL casirivimab 120 mg/ML Injection) } Pack [REGEN-COV 4/1]
(Atom ID: 12539665)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{1 (11.1 ML imdevimab 120 MG/ML Injection) / 4 (2.5 ML casirivimab 120 MG/ML Injection) } Pack [REGEN-COV 4/1]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2479156
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12539665
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
2479156
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.